A 42-year-old woman with bipolar disorder on haloperidol 10 mg/day for 3 months develops involuntary orofacial movements, tongue protrusion, and lip smacking. Which is the most common movement disorder associated with long-term antipsychotic use?

Explanation

## Most Common Long-Term Movement Disorder: Tardive Dyskinesia **Key Point:** Tardive dyskinesia (TD) is the most common *late-onset* movement disorder associated with chronic antipsychotic use, particularly typical antipsychotics. It develops after months to years of exposure. ### Definition & Epidemiology - **Onset:** Typically after ≥3 months of antipsychotic exposure (can occur earlier with high doses or in elderly) - **Incidence:** 3–5% per year of exposure; cumulative risk ~26% after 5 years on typical antipsychotics - **Risk factors:** Age >50 years, female sex, diabetes, mood disorders, higher antipsychotic doses ### Clinical Features **Orofacial dyskinesias (most common):** - Lip smacking, puckering, licking - Tongue protrusion and rolling - Jaw deviation and clenching - Buccal movements **Limb & trunk dyskinesias:** - Choreiform movements of arms and legs - Rocking, swaying - Finger movements ### Proposed Mechanisms ```mermaid flowchart TD A[Chronic D2 blockade]:::action --> B[Denervation supersensitivity<br/>of dopamine receptors]:::outcome B --> C[Upregulation of striatal<br/>dopamine receptors]:::outcome C --> D[Increased sensitivity to dopamine]:::outcome D --> E[Involuntary movements<br/>Tardive Dyskinesia]:::urgent A --> F[Oxidative stress &<br/>neuronal damage]:::outcome F --> E ``` **High-Yield:** The mechanism is thought to involve **denervation supersensitivity** — chronic dopamine blockade leads to upregulation and hypersensitivity of striatal dopamine receptors, resulting in dyskinetic movements even when dopamine levels normalize or the drug is withdrawn. ### Comparison: Timing of Antipsychotic-Induced Movement Disorders | Disorder | Onset | Duration | Reversibility | Typical Features | |----------|-------|----------|---------------|------------------| | **Acute dystonia** | Minutes to hours | Hours to days | Fully reversible | Muscle spasms, oculogyric crisis, torticollis | | **Akathisia** | Days to weeks | Days to weeks | Reversible | Restlessness, inability to sit still, anxiety | | **Parkinsonism** | Days to weeks | Days to weeks | Reversible | Rigidity, tremor, bradykinesia | | **Tardive dyskinesia** | Months to years | Persistent (often irreversible) | Partially/poorly reversible | Orofacial dyskinesias, choreiform movements | | **Neuroleptic malignant syndrome** | Hours to days | Hours to days (life-threatening) | Reversible with treatment | Fever, rigidity, altered mental status, rhabdomyolysis | ### Prevention & Management 1. **Prevention (most important):** - Use lowest effective dose - Prefer atypical antipsychotics (lower TD risk) - Regular monitoring with AIMS scale (Abnormal Involuntary Movement Scale) 2. **Management of established TD:** - Switch to atypical antipsychotic (especially quetiapine, clozapine) - Consider vesicular monoamine transporter 2 (VMAT2) inhibitors: tetrabenazine, valbenazine - Dose reduction if possible - Avoid anticholinergics (may worsen TD) **Clinical Pearl:** Unlike acute dystonia or akathisia, TD does *not* improve with anticholinergics and may worsen. This is a key distinguishing feature in exams. **Mnemonic:** **TARDIVE** = **T**ypical antipsychotics, **A**fter months/years, **R**eceptor supersensitivity, **D**yskinesias orofacial, **I**rreversible (often), **V**EMAT2 inhibitors help, **E**arly detection with AIMS. ### Why Other Options Are Not "Most Common" - **Neuroleptic malignant syndrome:** Rare (0.02–3% of patients), acute, life-threatening — not a "common" long-term effect. - **Acute dystonia:** Early-onset (hours to days), reversible, less common than TD in chronic use. - **Akathisia:** Early-onset (days to weeks), reversible — not the most common late-onset disorder. [cite:Stahl's Essential Psychopharmacology 6e Ch 5; Harrison 21e Ch 386]